Plain-English translation of NCT04797039 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial evaluates a treatment called MRI-guided cryoablation, which uses precise freezing technology to destroy small prostate tumors while being guided by detailed MRI images. The freezing system used in this study has already been approved by the FDA and has been used successfully at Mayo Clinic. Researchers want to monitor how well this technique works and collect data about how patients do after treatment.
For men with small, early-stage prostate cancers who want to avoid traditional surgery or radiation therapy, this treatment offers a less invasive option. The trial aims to gather real-world evidence about the safety and effectiveness of this freezing approach as a focused treatment for localized prostate cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the MRI-guided freezing procedure as your doctor would normally perform it to treat your prostate cancer. After treatment, you'll return for follow-up visits with your doctor at regular intervals (typically at 3–6 months, 12 months, 24 months, 36 months, 48 months, and 60 months) to check how you're healing and whether the treatment worked. Your doctor may ask you to come back more frequently if needed.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Sponsor
Mayo Clinic
Enrollment target
~100 participants
Started
December 2020
Primary completion
December 2030
Age range
30 Years – 100 Years
Sex
Male only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Desirae Howe-Clayton
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.